Drug shortage
Liraglutide Injection · Novo Nordisk, Inc.
FDA drug shortage · To Be Discontinued · updated Aug 25, 2026
Key facts
| Generic name | Liraglutide Injection |
|---|---|
| Company | Novo Nordisk, Inc. |
| Presentation | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) |
| Dosage form | Injection |
| Status | To Be Discontinued |
| Therapeutic category | Endocrinology/Metabolism |
| Package NDCs | 0169-2800-15 |
| First posted | Aug 25, 2026 |
| Last updated | Aug 25, 2026 |
| Discontinued | Aug 25, 2026 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: